ATE333275T1 - Indole-3-propionsäure, ihre salze und ester als arzneimittel - Google Patents

Indole-3-propionsäure, ihre salze und ester als arzneimittel

Info

Publication number
ATE333275T1
ATE333275T1 AT99908381T AT99908381T ATE333275T1 AT E333275 T1 ATE333275 T1 AT E333275T1 AT 99908381 T AT99908381 T AT 99908381T AT 99908381 T AT99908381 T AT 99908381T AT E333275 T1 ATE333275 T1 AT E333275T1
Authority
AT
Austria
Prior art keywords
indole
propionic acid
ester
salt
effective amount
Prior art date
Application number
AT99908381T
Other languages
English (en)
Inventor
Miguel A Pappolla
Blas Frangione
Jorge Ghiso
Burkhard Poeggeler
Original Assignee
Univ South Alabama
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Alabama, Univ New York filed Critical Univ South Alabama
Application granted granted Critical
Publication of ATE333275T1 publication Critical patent/ATE333275T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
AT99908381T 1998-02-23 1999-02-23 Indole-3-propionsäure, ihre salze und ester als arzneimittel ATE333275T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7555598P 1998-02-23 1998-02-23
US11256598P 1998-12-16 1998-12-16

Publications (1)

Publication Number Publication Date
ATE333275T1 true ATE333275T1 (de) 2006-08-15

Family

ID=26757006

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99908381T ATE333275T1 (de) 1998-02-23 1999-02-23 Indole-3-propionsäure, ihre salze und ester als arzneimittel

Country Status (17)

Country Link
US (1) US6395768B1 (de)
EP (1) EP1056452B1 (de)
JP (2) JP5627160B2 (de)
CN (1) CN1147299C (de)
AT (1) ATE333275T1 (de)
AU (1) AU757925B2 (de)
BR (1) BR9908165A (de)
CA (1) CA2321455C (de)
DE (1) DE69932414T2 (de)
DK (1) DK1056452T3 (de)
EA (1) EA005244B1 (de)
ES (1) ES2270585T3 (de)
IL (2) IL137848A0 (de)
MX (1) MXPA00008216A (de)
NZ (1) NZ506260A (de)
PT (1) PT1056452E (de)
WO (1) WO1999042102A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6419916B1 (en) 1999-06-01 2002-07-16 The Regents Of The University Of California Assay for compounds which affect conformationally altered proteins
US6719988B2 (en) 1997-02-21 2004-04-13 The Regents Of The University Of California Antiseptic compositions for inactivating prions
US6322802B1 (en) 1999-06-01 2001-11-27 The Regents Of The University Of California Method of sterilizing
US6720355B2 (en) 1997-02-21 2004-04-13 The Regents Of The University Of California Sodium dodecyl sulfate compositions for inactivating prions
DE10006139A1 (de) * 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl-Derivate
US7491699B2 (en) 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
EP1583713B1 (de) 2003-01-07 2009-03-25 Ramot at Tel Aviv University Ltd. Peptidenanostrukturen die fremdmaterial enthalten, und verfahren zur herstellung derselben
US7348338B2 (en) * 2003-07-17 2008-03-25 Plexxikon, Inc. PPAR active compounds
KR101415503B1 (ko) * 2003-07-17 2014-07-04 플렉시콘, 인코퍼레이티드 Ppar 활성 화합물
US7125861B2 (en) * 2003-07-31 2006-10-24 Rolland F Hebert Water-soluble chitosan-indole-3-propionic acid conjugates
WO2005027901A1 (en) 2003-09-25 2005-03-31 Tel Aviv University Future Technology Development L.P. Compositions and methods using same for treating amyloid-associated diseases
WO2005031362A2 (en) 2003-10-02 2005-04-07 Ramot At Tel Aviv University Ltd. Novel antibacterial agents and methods of identifying and utilizing same
US20070105937A1 (en) * 2003-12-22 2007-05-10 Miguel Pappolla Indole-3-propionamide and derivatives thereof
WO2006013552A2 (en) 2004-08-02 2006-02-09 Ramot At Tel Aviv University Ltd. Articles of peptide nanostructures and method of forming the same
US7732479B2 (en) 2004-08-19 2010-06-08 Tel Aviv University Future Technology Development L.P. Compositions for treating amyloid associated diseases
JP2008521831A (ja) * 2004-11-30 2008-06-26 プレキシコン,インコーポレーテッド Ppar活性化合物
US7531568B2 (en) * 2004-11-30 2009-05-12 Plexxikon, Inc. PPAR active compounds
EP1893576A4 (de) * 2005-05-27 2010-03-17 Univ Kingston Behandlung von proteinfaltungsstörungen
EP1940767A2 (de) * 2005-09-07 2008-07-09 Plexxikon, Inc. Ppar-aktive verbindungen
AU2006287528A1 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. 1 , 4 and 1 , 5-disubstituted indole derivatives for use as PPAR active compounds
EP1973928A2 (de) 2005-10-11 2008-10-01 Ramot at Tel-Aviv University Ltd. Selbstzusammengebaute fmoc-ff-hydrogele
AU2007286651A1 (en) * 2006-08-23 2008-02-28 Intellect Neurosciences Inc. 3-(3-indolyl) propionic acid calcium salt and method of making 3-(3-indolyl) propionic acid free acid therefrom
PE20090159A1 (es) * 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
US9744155B2 (en) * 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
WO2015116988A2 (en) * 2014-01-31 2015-08-06 Counterpoint Health Solutions, Inc. Covalently bound metabolites as biomarkers
CN108125950B (zh) * 2017-12-28 2020-09-25 崔明 吲哚丙酸在制备用于预防和/或治疗肿瘤放疗副反应的药物中的用途
JP2020083827A (ja) * 2018-11-27 2020-06-04 国立研究開発法人農業・食品産業技術総合研究機構 ケミカルシャペロンまたは神経細胞死の抑制剤
US11041847B1 (en) 2019-01-25 2021-06-22 Ixcela, Inc. Detection and modification of gut microbial population
CN109674787A (zh) * 2019-02-01 2019-04-26 百迈康生物医药科技(广州)有限公司 一种防治缺血性心脏病的药物及其应用
CN109730993A (zh) * 2019-02-28 2019-05-10 北京大学人民医院(北京大学第二临床医学院) 吲哚丙酸在制备防治类风湿关节炎药物中的应用
WO2020185913A1 (en) * 2019-03-12 2020-09-17 Intellect Neurosciences, Inc. Indole-3-propionic acids and salts and esters thereof for treating skin disorders
US20230038360A1 (en) * 2019-12-20 2023-02-09 Basf Se Composition for the treatment of amyloid-beta associated diseases
CN118141804A (zh) * 2024-03-06 2024-06-07 浙江大学 吲哚-3-丙酸在制备用于增敏肿瘤免疫治疗的药物中的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536505A (en) * 1983-05-17 1985-08-20 Ciba-Geigy Corporation Certain N-(pyridyl) indoles
JP2602735B2 (ja) * 1989-09-27 1997-04-23 株式会社大塚製薬工場 抗活性酸素剤
JPH0578248A (ja) * 1991-03-04 1993-03-30 Mitsubishi Gas Chem Co Inc 活性酸素消去剤
JPH0578247A (ja) * 1991-03-04 1993-03-30 Mitsubishi Gas Chem Co Inc 活性酸素消去剤
WO1993010087A1 (en) * 1991-11-18 1993-05-27 G.D. Searle & Co. Derivatives of cyclic phenolic thioethers as inhibitors or stimulators of superoxide generation
CA2140440A1 (en) * 1992-08-06 1994-02-17 Ellen M. Dobrusin 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
IT1265101B1 (it) * 1993-07-23 1996-10-30 Erba Carlo Spa Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
JPH0881442A (ja) * 1994-07-14 1996-03-26 Otsuka Pharmaceut Co Ltd 環状アミド誘導体
RU2152385C1 (ru) * 1994-07-27 2000-07-10 Санкио Компани Лимитед Гетероциклические соединения, применимые в качестве аллостерических эффекторов при мускариновых рецепторах
JPH08175993A (ja) * 1994-12-21 1996-07-09 Green Cross Corp:The 抗酸化剤
JPH09249567A (ja) * 1996-01-12 1997-09-22 Otsuka Pharmaceut Co Ltd 医薬組成物
TW430660B (en) * 1996-05-30 2001-04-21 Mochida Pharm Co Ltd Novel benzindole derivatives for neuron cell protection, processes for production, and the pharmaceutical compounds containing them

Also Published As

Publication number Publication date
EP1056452B1 (de) 2006-07-19
DK1056452T3 (da) 2006-11-20
PT1056452E (pt) 2006-12-29
IL137848A0 (en) 2001-10-31
CN1292693A (zh) 2001-04-25
BR9908165A (pt) 2000-10-31
AU2782899A (en) 1999-09-06
JP5627160B2 (ja) 2014-11-19
JP2002503691A (ja) 2002-02-05
DE69932414T2 (de) 2007-02-22
CA2321455C (en) 2010-10-19
WO1999042102A8 (en) 2001-02-15
EP1056452A1 (de) 2000-12-06
AU757925B2 (en) 2003-03-13
WO1999042102A1 (en) 1999-08-26
DE69932414D1 (de) 2006-08-31
CN1147299C (zh) 2004-04-28
EA005244B1 (ru) 2004-12-30
JP2012017343A (ja) 2012-01-26
US6395768B1 (en) 2002-05-28
MXPA00008216A (es) 2004-11-22
CA2321455A1 (en) 1999-08-26
HK1036588A1 (en) 2002-01-11
ES2270585T3 (es) 2007-04-01
NZ506260A (en) 2003-05-30
IL137848A (en) 2010-11-30
EA200000874A1 (ru) 2001-02-26

Similar Documents

Publication Publication Date Title
DE69932414D1 (de) Indole-3-propionsäure, ihre salze und ester als arzneimittel
DE69822832D1 (de) Therapeutische und lebensmittel-zusammensetzungen, welche essentielle fettsäuren und bioaktive disulfide enthalten
ATE252901T1 (de) Arzneimittel zur behandlung von entzündlichen herzkrankheiten
DE69004081D1 (de) Verwendung der Stearidonsäure zur Behandlung von Entzündungserkrankungen.
ATE267798T1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
PT801649E (pt) Derivados de hidroxilamina uteis para aumentar a producao de proteinas moleculares adventicias e sua preparacao
NO157020C (no) AnalogifremgangsmŸte ved fremstilling av terapeutisk aktive 3,20-dioxo-1,4-pregnadien-17alfa-ol-17-aromatiske heterocykliske carboxylater.
NO904378D0 (no) Fremgangsmaate for fremstilling av et modifisert protein for terapeutisk anvendelse.
DE59811158D1 (de) Verwendung von erythropoietin und eisenpräparaten zur herstellung von pharmazeutischen kombinationspräparaten zur behandlung von rheumatischen erkrankungen
ATE336997T1 (de) Fulvinsäure und dessen verwendung zur behandlung von diversen krankheitszuständen
NO166939C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive carboxylsyrederivater.
EP0839529A3 (de) Zubereitungen enthaltend Ester oder Amide von alipatischen Monocarbonsäuren zur Behandlung von Hautkrankheiten
DE69635670D1 (de) Threitol-buttersäureester-enthaltende zusammensetzungen und ihre verwendung
DE60115432D1 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
DE69725882D1 (de) Adenovirus e4 proteine für induktion von zelltod
DE69939075D1 (de) Pharmazeutische Zusammenstellung zur Vorbeugung und Behandlung von mit Zellkrankheiten des Augenhintergrundes zusammenhängenden Krankheiten
ITRM930365A0 (it) Uso di esteri sull'ossidrile della l-carnitina con acidi aromatici perprodurre composizioni farmaceutiche per il trattamento di affezioni cutanee.
ATE90563T1 (de) Arzneimittelzubereitung aus esterderivaten des hecogenins und dessen verwendung zur behandlung von benigner prostatahyperplasie.
ATE316379T1 (de) Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
ES2044170T3 (es) Sal de estroncio, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen.
DE69927260D1 (de) Topische pharmazeutische zusammensetzung zur behandlung von haut- oder zirkulatorischen krankheiten auf inflammatorischer, immun-, proliferativer oder degenerativer basis
ATE5256T1 (de) Phenylpiperazinderivate von 1,3,4oxadiazolylphenolen, ihre herstellung und diese enthaltende therapeutische mittel.
FI891210A7 (fi) Tiosulfiinihappojohdannaiset, niiden käyttö tulehdussairauksien käsitt elyyn sekä näitä aineita sisältävät lääkeaineet
DE3883335D1 (de) Brenzcatechincarbonsaeurederivate, ihre herstellung und verwendung als wirkstoffe fuer arzneimittel.
NO890801D0 (no) Fremgangsmaate for fremstilling av lysyloxydaseinhibitorer.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1056452

Country of ref document: EP